Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/virtualmentor.2003.5.2.mhum1-0302 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
subspecies (MAP) and Crohn's disease: the debate continues.
Transl Gastroenterol Hepatol
July 2023
Division of Gastroenterology and Hepatology, New York Presbyterian Hospital-Weill, Cornell Medicine, New York, NY, USA.
Crohn's disease (CD) in humans and Johne's disease (JD) in ruminants share numerous clinical and pathologic similarities. As subspecies (MAP) is known to fulfill Koch's postulates as the cause of JD, there has been considerable debate over the past century about whether MAP also plays a role in CD. With recent advances in MAP identification techniques, we can now demonstrate a higher presence of MAP in CD patients compared to the general population.
View Article and Find Full Text PDFPhase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung Cancer.
Clin Cancer Res
June 2022
Duke Cancer Institute, Durham, North Carolina.
Purpose: The adenosine 2A receptor (A2AR) mediates the immunosuppressive effects of adenosine in the tumor microenvironment and is highly expressed in non-small cell lung cancer (NSCLC). Taminadenant (PBF509/NIR178) is an A2AR antagonist able to reactivate the antitumor immune response.
Patients And Methods: In this phase I/Ib, dose-escalation/expansion study, patients with advanced/metastatic NSCLC and ≥1 prior therapy received taminadenant (80-640 mg, orally, twice a day) with or without spartalizumab (anti-programmed cell death-1, 400 mg, i.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!